|COA||Certificate of Analysis-Tasimelteon 609799-22-6 B16TSMT0425|
|Description||Tasimelteon (trade name Hetlioz) is a drug approved by the FDA solely for the treatment of non-24-hour sleep–wake disorder (often designated as N24HSWD) in totally blind adults. It is a selective agonist for the melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, similar to other members of the melatonin receptor agonist class of which ramelteon (2005) and agomelatine (2009) were the first approved.|
|B0084-072984||100 mg||$498||In stock|
|B0084-072984||1 g||$899||In stock|
|Brife Description||Tasimelteon is a novel circadian regulator, is the first product for the treatment of Non-24-hour Sleep-Wake Disorder (Non-24) approved by either the FDA or the European Medicines Agency (EMA).It is also a melatonin MT1 and MT2 receptor agonist.|
|Appearance||White to off-white Solid|
|Synonyms||BMS-214,778; BMS-214778; BMS214778; BMS 214778. VEC-162; VEC162; VEC 162. Trade name: Hetlioz.|
|Application||Tasimelteon is a novel drug, used in the treatment of non-24 hour sleep-wake disorder. It helps to correct the circadian rhythm disorder often seen in patients who are visually impaired.|
|Quality Standard||In-house Standard|
|Boiling Point||442.6±24.0 °C | Condition: Press: 760 Torr|
|Melting Point||57 - 65°C|
Tasimelteon (trade name Hetlioz) is a drug approved by the FDA solely for the treatment of non-24-hour sleep–wake disorder (often designated as N24HSWD) in tota...
Ramelteon has high affinity with recombinant human MT1 and MT2 receptors with pKi of 10.05 and 9.70, respectively.
This active molecular is high affinity nonselective melatonin receptors MT1 and MT2 agonist which is under development for the treatment of insomnia and other s...